Nicotine, Toxicants Up With Smokeless Tobacco Exposure

This article originally appeared here.
Share this content:
Nicotine, Toxicants Up With Smokeless Tobacco Exposure
Nicotine, Toxicants Up With Smokeless Tobacco Exposure

WEDNESDAY, Nov. 18, 2015 (HealthDay News) -- Smokeless tobacco users have higher levels of nicotine and carcinogenic tobacco-specific nitrosamines compared with exclusive cigarette smokers, according to a study published online Nov. 18 in Cancer Epidemiology, Biomarkers & Prevention.

Brian L. Rostron, Ph.D., M.P.H., from the U.S. Food and Drug Administration in Silver Spring, Md., and colleagues analyzed biomarkers of tobacco exposure (serum cotinine, urinary 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol [NNAL], blood lead, blood cadmium, blood mercury, urinary arsenic, and urinary N-acetyl-S-(2-cyanoethyl)-L-cysteine) for 23,684 adult participants from the National Health and Nutrition Examination Survey from 1999 to 2012.

The researchers found that, compared with exclusive cigarette smokers, exclusive smokeless tobacco users had higher geometric mean concentrations of serum cotinine (178.9 versus 130.6 ng/mL) and NNAL (583.0 versus 217.6 pg/mg creatinine). Compared with nontobacco users, smokeless tobacco users also had higher concentrations of blood lead (adjusted geometric mean ratio, 1.30). From 2007-2008 to 2011-2012 there was a decline in NNAL concentrations for smokeless tobacco users (geometric mean, 1,013.7 to 325.7 pg/mg creatinine, respectively), based on limited sample sizes.

"Exclusive smokeless tobacco users have higher observed levels of exposure to nicotine and carcinogenic tobacco-specific nitrosamines, as measured by cotinine and NNAL biomarker concentrations, than exclusive cigarette smokers," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »